BRTX (BioRestorative Therapies) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


BRTX BioRestorative Therapies Inc BRTX
51 GF Score
Price $0.39
GF Value $1.52
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioRestorative Therapies's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BRTX vs KPRX, INTS, ERNA: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Margin of Safety % (DCF Earnings Based) falls into.


BRTX
51GF Score
BioRestorative Therapies Inc BRTX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioRestorative Therapies (BRTX) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of $0.39 is trading 74.1% below its estimated GF Value™ of $1.52. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for BRTX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $1.52 vs. price of $0.39 (74.1% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the BRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioRestorative Therapies Business Description

Other Exchanges 9OF:Germany
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score

Get the complete analysis for BRTX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$1.52
GF Value